GLIS1

Across TCGA pan-cancer cohorts, GLIS1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GLIS1 data layer compared with 26 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher GLIS1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GLIS1 expression acts as an unfavorable survival marker.

BLCA, PRAD, and LUAD are the cancer types where GLIS1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	III,IV	0.057	0.684	<.001	24	view →
PRAD	DFS	Median	All	0.617	0.886	.020	6	view →
LUAD	DFS	Median	All	0.225	0.678	<.001	6	view →
READ	OS	Median	All	0.281	0.830	.006	3	view →
SKCM	OS	Median	IV	0.415	0.861	.014	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

GLIS1–BLCA (OS)

Open the BLCA breakdown →